{"entity":{"type":"insider","cik":"0001995218","url":"/insider/0001995218","json_url":"/insider/0001995218.json","name":"Townsend Richard Nolan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":19,"first":"2024-05-14","last":"2026-08-19","span_basis":"filed_date"},"name_variants":[{"name":"Townsend Richard Nolan","source":"filing","n_filings":19,"first_seen":"2024-05-14","last_seen":"2026-08-19"}],"transactions":[{"id":9298219,"accession":"0001995218-26-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001995218-26-000015","line_url":"/filing/0001995218-26-000015#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3345.0,"shares_display":"3,345","price_per_share":4.9512,"price_display":"4.95","price_state":"stated","total_value":16561.764,"total_display":"16,561.76","total_whole":"16,562","shares_owned_after":374472.0,"shares_owned_after_display":"374,472","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-19","scope":"insider"},{"id":5780070,"accession":"0001995218-26-000013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001995218-26-000013","line_url":"/filing/0001995218-26-000013#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25947.0,"shares_display":"25,947","price_per_share":4.48,"price_display":"4.48","price_state":"stated","total_value":116242.56,"total_display":"116,242.56","total_whole":"116,243","shares_owned_after":377817.0,"shares_owned_after_display":"377,817","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-01","scope":"insider"},{"id":5972150,"accession":"0001995218-26-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001995218-26-000011","line_url":"/filing/0001995218-26-000011#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3342.0,"shares_display":"3,342","price_per_share":5.0649,"price_display":"5.06","price_state":"stated","total_value":16926.8958,"total_display":"16,926.90","total_whole":"16,927","shares_owned_after":336764.0,"shares_owned_after_display":"336,764","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-18","filed_date":"2026-05-20","scope":"insider"},{"id":5877706,"accession":"0001995218-26-000009","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001995218-26-000009","line_url":"/filing/0001995218-26-000009#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55000.0,"shares_display":"55,000","price_per_share":5.6934,"price_display":"5.69","price_state":"stated","total_value":313137.0,"total_display":"313,137.00","total_whole":"313,137","shares_owned_after":340106.0,"shares_owned_after_display":"340,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-06","filed_date":"2026-04-07","scope":"insider"},{"id":5841687,"accession":"0001995218-26-000004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001995218-26-000004","line_url":"/filing/0001995218-26-000004#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10173.0,"shares_display":"10,173","price_per_share":6.382,"price_display":"6.38","price_state":"stated","total_value":64924.086,"total_display":"64,924.09","total_whole":"64,924","shares_owned_after":392483.0,"shares_owned_after_display":"392,483","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-18","filed_date":"2026-02-20","scope":"insider"},{"id":4054432,"accession":"0001995218-25-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001995218-25-000007","line_url":"/filing/0001995218-25-000007#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1127.0,"shares_display":"1,127","price_per_share":9.27,"price_display":"9.27","price_state":"stated","total_value":10447.29,"total_display":"10,447.29","total_whole":"10,447","shares_owned_after":240991.0,"shares_owned_after_display":"240,991","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-20","scope":"insider"},{"id":4104545,"accession":"0001995218-25-000005","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001995218-25-000005","line_url":"/filing/0001995218-25-000005","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13133.0,"shares_display":"13,133","price_per_share":8.942054595294296,"price_display":"8.94","price_state":"stated","total_value":117436.003,"total_display":"117,436.00","total_whole":"117,436","shares_owned_after":242266.0,"shares_owned_after_display":"242,266","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-17","filed_date":"2025-10-17","scope":"insider","n_lines":2},{"id":9287369,"accession":"0001415889-25-024104","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-024104","line_url":"/filing/0001415889-25-024104#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1115.0,"shares_display":"1,115","price_per_share":4.668,"price_display":"4.67","price_state":"stated","total_value":5204.82,"total_display":"5,204.82","total_whole":"5,205","shares_owned_after":220058.0,"shares_owned_after_display":"220,058","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-09-10","scope":"insider"},{"id":5081479,"accession":"0001415889-25-022473","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-022473","line_url":"/filing/0001415889-25-022473#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2735.0,"shares_display":"2,735","price_per_share":4.668,"price_display":"4.67","price_state":"stated","total_value":12766.98,"total_display":"12,766.98","total_whole":"12,767","shares_owned_after":220058.0,"shares_owned_after_display":"220,058","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4589680,"accession":"0001415889-25-013819","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-013819","line_url":"/filing/0001415889-25-013819#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1074.0,"shares_display":"1,074","price_per_share":2.774,"price_display":"2.77","price_state":"stated","total_value":2979.276,"total_display":"2,979.28","total_whole":"2,979","shares_owned_after":221173.0,"shares_owned_after_display":"221,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-16","filed_date":"2025-05-20","scope":"insider"},{"id":4035712,"accession":"0001415889-25-005113","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-005113","line_url":"/filing/0001415889-25-005113#line-1","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4326.0,"shares_display":"4,326","price_per_share":4.413,"price_display":"4.41","price_state":"stated","total_value":19090.638,"total_display":"19,090.64","total_whole":"19,091","shares_owned_after":220119.0,"shares_owned_after_display":"220,119","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-19","filed_date":"2025-02-21","scope":"insider"},{"id":2102844,"accession":"0001415889-24-029143","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-029143","line_url":"/filing/0001415889-24-029143#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":8.1965,"price_display":"8.20","price_state":"stated","total_value":20491.25,"total_display":"20,491.25","total_whole":"20,491","shares_owned_after":120695.0,"shares_owned_after_display":"120,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider"},{"id":3178839,"accession":"0001415889-24-026737","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-026737","line_url":"/filing/0001415889-24-026737#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":7.8227,"price_display":"7.82","price_state":"stated","total_value":19556.75,"total_display":"19,556.75","total_whole":"19,557","shares_owned_after":120695.0,"shares_owned_after_display":"120,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-11","filed_date":"2024-11-13","scope":"insider"},{"id":2223116,"accession":"0001415889-24-025110","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-025110","line_url":"/filing/0001415889-24-025110#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":8.0991,"price_display":"8.10","price_state":"stated","total_value":40495.5,"total_display":"40,495.50","total_whole":"40,496","shares_owned_after":120695.0,"shares_owned_after_display":"120,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-10","filed_date":"2024-10-15","scope":"insider"},{"id":2156632,"accession":"0001415889-24-023233","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023233","line_url":"/filing/0001415889-24-023233#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":10.6547,"price_display":"10.65","price_state":"stated","total_value":53273.5,"total_display":"53,273.50","total_whole":"53,274","shares_owned_after":120695.0,"shares_owned_after_display":"120,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-11","scope":"insider"},{"id":2190496,"accession":"0001415889-24-021245","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-021245","line_url":"/filing/0001415889-24-021245#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":11.5269,"price_display":"11.53","price_state":"stated","total_value":57634.5,"total_display":"57,634.50","total_whole":"57,635","shares_owned_after":120695.0,"shares_owned_after_display":"120,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-12","filed_date":"2024-08-13","scope":"insider"},{"id":2391923,"accession":"0001415889-24-019526","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-019526","line_url":"/filing/0001415889-24-019526","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28031.0,"shares_display":"28,031","price_per_share":17.067134957725376,"price_display":"17.07","price_state":"stated","total_value":478408.86,"total_display":"478,408.86","total_whole":"478,409","shares_owned_after":120795.0,"shares_owned_after_display":"120,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-11","filed_date":"2024-07-12","scope":"insider","n_lines":2},{"id":2391917,"accession":"0001415889-24-019526","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-019526","line_url":"/filing/0001415889-24-019526","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26969.0,"shares_display":"26,969","price_per_share":16.499642181764248,"price_display":"16.50","price_state":"stated","total_value":444978.85,"total_display":"444,978.85","total_whole":"444,979","shares_owned_after":152073.0,"shares_owned_after_display":"152,073","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-10","filed_date":"2024-07-12","scope":"insider","n_lines":2},{"id":2101445,"accession":"0001415889-24-016518","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-016518","line_url":"/filing/0001415889-24-016518","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":17.652764,"price_display":"17.65","price_state":"stated","total_value":88263.82,"total_display":"88,263.82","total_whole":"88,264","shares_owned_after":172733.0,"shares_owned_after_display":"172,733","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-10","filed_date":"2024-06-12","scope":"insider","n_lines":2},{"id":2895151,"accession":"0000950170-24-059506","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-059506","line_url":"/filing/0000950170-24-059506#line-2","is_derivative":false,"issuer_cik":"0001907108","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001907108","owner_cik":"0001995218","owner_name":"Townsend Richard Nolan","owner_display_name":"Townsend Richard Nolan","owner_url":"/insider/0001995218","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":13.2186,"price_display":"13.22","price_state":"stated","total_value":66093.0,"total_display":"66,093.00","total_whole":"66,093","shares_owned_after":170695.0,"shares_owned_after_display":"170,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-13","filed_date":"2024-05-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":24,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001907108","name":"Lexeo Therapeutics, Inc.","url":"/issuer/0001907108","role":"Director, Officer (Chief Executive Officer)","n_filings":19,"first_seen":"2024-05-14","last_seen":"2026-08-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001995218","retrieved_at":"2026-08-24T22:24:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}